An effective oral rotavirus vaccine has now been licensed by the NIH Office of Technology Transfer to BIOVIRx, Inc., of Minneapolis, Minnesota.
BIOVIRx plans global commercialization of the vaccine.
Rotaviruses are consistently shown to be the leading cause of severe diarrhea in infants and young children.
|Rotoviruses cause up to 592,000 deaths annually.|
Worldwide they cause more than 135 million episodes of diarrhea each year in infants and children younger than 5 years old. This results in up to 592,000 deaths annually.
Symptoms of rotavirus infection develop quickly and in addition to diarrhea, may include vomiting, fever and dehydration. The resulting dehydration can be reversed through oral rehydration therapy or, in more serious cases, through hospitalization and intravenous fluids.
Although effective, these therapies are not readily available or used in many parts of the developing world. Children in developing countries are more vulnerable to severe and fatal illness.